Original Article

You have free access to this content

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

  1. Alfonso Quintás-Cardama MD1,
  2. Fabio Pires De Souza Santos MD1,
  3. Hagop Kantarjian MD1,
  4. Susan O'Brien MD1,
  5. Stefan Faderl MD1,
  6. Ahmed Awais MD2,
  7. Gautam Borthakur MD1,
  8. Jorge Cortes MD1,†,*

Article first published online: 10 JUN 2009

DOI: 10.1002/cncr.24432

Issue

Cancer

Cancer

Volume 115, Issue 17, pages 3935–3943, 1 September 2009

Additional Information

How to Cite

Quintás-Cardama, A., De Souza Santos, F. P., Kantarjian, H., O'Brien, S., Faderl, S., Awais, A., Borthakur, G. and Cortes, J. (2009), Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer, 115: 3935–3943. doi: 10.1002/cncr.24432

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Internal Medicine, Memorial Hermann Hospital, The University of Texas, Houston, Texas

  1. †

    Fax: (713) 794-4297

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030

Publication History

  1. Issue published online: 20 AUG 2009
  2. Article first published online: 10 JUN 2009
  3. Manuscript Accepted: 22 JAN 2009
  4. Manuscript Revised: 15 JAN 2009
  5. Manuscript Received: 1 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (160K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Massimo Breccia, Giuliana Alimena, Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients, BioDrugs, 2011, 25, 3, 147

    CrossRef

  2. 2
    A. Mazharian, C. Ghevaert, L. Zhang, S. Massberg, S. P. Watson, Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation, Blood, 2011, 117, 19, 5198

    CrossRef

  3. 3
    Fabio P. S. Santos, Hagop Kantarjian, Alfonso Quintás-Cardama, Jorge Cortes, Evolution of Therapies for Chronic Myelogenous Leukemia, The Cancer Journal, 2011, 17, 6, 465

    CrossRef

  4. 4
    Mary Beth Rios, Patricia Ault, Identification of Side Effects Associated With Intolerance to BCR-ABL Inhibitors in Patients With Chronic Myeloid Leukemia, Clinical Journal of Oncology Nursing, 2011, 15, 6, 660

    CrossRef

  5. 5
    Javier Pinilla-Ibarz, Jorge Cortes, Michael J. Mauro, Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia, Cancer, 2011, 117, 4
    Direct Link:
  6. 6
    Fabio P. S. Santos, Yesid Alvarado, Hagop Kantarjian, Dushyant Verma, Susan O'Brien, Gloria Mattiuzzi, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib, Cancer, 2011, 117, 5
    Direct Link:
  7. 7
    E Jabbour, M Deininger, A Hochhaus, Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia, Leukemia, 2010, 25, 2, 201

    CrossRef

View Full Article (HTML) Get PDF (160K)